{"id":"comparator-placebo-to-mk-0518","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Elevated creatine kinase"}]},"_chembl":{"chemblId":"CHEMBL5992860","moleculeType":null,"molecularWeight":"426.25"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MK-0518 (raltegravir) inhibits HIV integrase, an enzyme essential for viral replication. By blocking integrase-mediated strand transfer, the drug prevents integration of viral DNA into the host genome, thereby blocking HIV replication. This represents a novel class of antiretroviral therapy targeting a distinct step in the HIV life cycle.","oneSentence":"MK-0518 is an integrase strand transfer inhibitor that blocks HIV integrase, preventing the virus from inserting its genetic material into human DNA.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:08.361Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced patients"}]},"trialDetails":[{"nctId":"NCT02131233","phase":"PHASE3","title":"Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-05-23","conditions":"HIV Infection","enrollment":802},{"nctId":"NCT00843713","phase":"PHASE4","title":"Effect of Raltegravir on Endothelial Function in HIV-Infected Patients","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2009-01","conditions":"HIV Infection, Inflammation, Cardiovascular Disease","enrollment":56},{"nctId":"NCT00443703","phase":"PHASE3","title":"MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-032)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-05","conditions":"HIV Infection","enrollment":352},{"nctId":"NCT00369941","phase":"PHASE3","title":"A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-08","conditions":"HIV Infections","enrollment":566},{"nctId":"NCT00443729","phase":"PHASE3","title":"MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-033)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-05","conditions":"HIV Infection","enrollment":355},{"nctId":"NCT00745823","phase":"PHASE3","title":"A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-09","conditions":"HIV","enrollment":775},{"nctId":"NCT00293254","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (0518-019)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-02","conditions":"HIV Infections","enrollment":351},{"nctId":"NCT00105157","phase":"PHASE2","title":"Safety and Efficacy of an Investigational Drug in Human Immunodeficiency Virus (HIV)-Infected Patients Failing Current Antiretroviral Therapies (0518-005)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03","conditions":"HIV Infections, Acquired Immunodeficiency Syndrome","enrollment":179},{"nctId":"NCT00100048","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-01","conditions":"HIV Infections, Acquired Immunodeficiency Syndrome","enrollment":206},{"nctId":"NCT00293267","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-02","conditions":"HIV Infections","enrollment":352}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Comparator: Placebo to MK-0518","genericName":"Comparator: Placebo to MK-0518","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MK-0518 is an integrase strand transfer inhibitor that blocks HIV integrase, preventing the virus from inserting its genetic material into human DNA. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}